SMARCA4 and neoplasm: SMARCA4, commonly mutated in various tumors, is associated with reduced sensitivity to traditional cancer treatments.736,737 Inhibiting SMARCA4/2 is an effective strategy for curbing tumor growth and improving patient outcomes.